Literature DB >> 22821210

Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection.

Linda J W Bosch1, Sandra Mongera, Jochim S Terhaar Sive Droste, Frank A Oort, Sietze T van Turenhout, Maarten T Penning, Joost Louwagie, Chris J J Mulder, Manon van Engeland, Beatriz Carvalho, Gerrit A Meijer.   

Abstract

BACKGROUND: Stool-based molecular tests hold large potential for improving colorectal cancer screening. Here, we investigated the analytical sensitivity of a DNA methylation assay on partial stool samples, and estimated the DNA degradation in stool over time. In addition, we explored the detection of DNA methylation in fecal immunochemical test (FIT) fluid.
MATERIALS AND METHODS: Partial stool samples of colonoscopy-negative individuals were homogenized with stool homogenization buffer, spiked with different numbers of HCT116 colon cancer cells and kept at room temperature for 0, 24, 48, 72 and 144 h before DNA isolation. Analytical sensitivity was determined by the lowest number of cells that yielded positive test results by DNA methylation or mutation analysis. DNA methylation in FIT fluid was measured in 11 CRC patients and 20 control subjects.
RESULTS: The analytical sensitivity for detecting DNA methylation was 3000 cells per gram stool, compared to 60000 cells per gram stool for detection of DNA mutations in the same stool samples. No degradation up to 72 h was noted when a conservation buffer was used. DNA methylation was detected in 4/11 CRC FIT samples and in none of the 20 control FIT samples.
CONCLUSIONS: Methylation based stool DNA testing showed a high analytical sensitivity for tumor DNA in partial stool samples, which was hardly influenced by DNA degradation over time, provided an adequate buffer was used. The feasibility of detecting DNA methylation in FIT fluid demonstrates the opportunity to combine testing for occult blood with DNA methylation in the same collection device.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22821210     DOI: 10.1007/s13402-012-0092-6

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  27 in total

1.  DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests.

Authors:  Jeff Olson; Duncan H Whitney; Kristine Durkee; Anthony P Shuber
Journal:  Diagn Mol Pathol       Date:  2005-09

2.  Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.

Authors:  Thomas F Imperiale; David F Ransohoff; Steven H Itzkowitz; Barry A Turnbull; Michael E Ross
Journal:  N Engl J Med       Date:  2004-12-23       Impact factor: 91.245

Review 3.  Molecular tests for colorectal cancer screening.

Authors:  Linda J W Bosch; Beatriz Carvalho; Remond J A Fijneman; Connie R Jimenez; Herbert M Pinedo; Manon van Engeland; Gerrit A Meijer
Journal:  Clin Colorectal Cancer       Date:  2011-03-01       Impact factor: 4.481

4.  DNA methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT.

Authors:  Linda J W Bosch; Frank A Oort; Maarten Neerincx; Carolina A J Khalid-de Bakker; Jochim S Terhaar sive Droste; Veerle Melotte; Daisy M A E Jonkers; Ad A M Masclee; Sandra Mongera; Madeleine Grooteclaes; Joost Louwagie; Wim van Criekinge; Veerle M H Coupé; Chris J Mulder; Manon van Engeland; Beatriz Carvalho; Gerrit A Meijer
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-01

5.  A quantitative immunochemical fecal occult blood test for colorectal neoplasia.

Authors:  Zohar Levi; Paul Rozen; Rachel Hazazi; Alex Vilkin; Amal Waked; Eran Maoz; Shlomo Birkenfeld; Moshe Leshno; Yaron Niv
Journal:  Ann Intern Med       Date:  2007-02-20       Impact factor: 25.391

6.  Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer.

Authors:  Myoung Sook Kim; Joost Louwagie; Beatriz Carvalho; Jochim S Terhaar Sive Droste; Hannah Lui Park; Young Kwang Chae; Keishi Yamashita; Junwei Liu; Kimberly Laskie Ostrow; Shizhang Ling; Rafael Guerrero-Preston; Semra Demokan; Zubeyde Yalniz; Nejat Dalay; Gerrit A Meijer; Wim Van Criekinge; David Sidransky
Journal:  PLoS One       Date:  2009-08-07       Impact factor: 3.240

7.  Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer.

Authors:  Sabine C Glöckner; Mashaal Dhir; Joo Mi Yi; Kelly E McGarvey; Leander Van Neste; Joost Louwagie; Timothy A Chan; Wolfram Kleeberger; Adriaan P de Bruïne; Kim M Smits; Carolina A J Khalid-de Bakker; Daisy M A E Jonkers; Reinhold W Stockbrügger; Gerrit A Meijer; Frank A Oort; Christine Iacobuzio-Donahue; Katja Bierau; James G Herman; Stephen B Baylin; Manon Van Engeland; Kornel E Schuebel; Nita Ahuja
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

8.  Stool DNA and occult blood testing for screen detection of colorectal neoplasia.

Authors:  David A Ahlquist; Daniel J Sargent; Charles L Loprinzi; Theodore R Levin; Douglas K Rex; Dennis J Ahnen; Kandice Knigge; M Peter Lance; Lawrence J Burgart; Stanley R Hamilton; James E Allison; Michael J Lawson; Mary E Devens; Jonathan J Harrington; Shauna L Hillman
Journal:  Ann Intern Med       Date:  2008-10-07       Impact factor: 25.391

9.  GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer.

Authors:  Debby M E I Hellebrekers; Marjolein H F M Lentjes; Sandra M van den Bosch; Veerle Melotte; Kim A D Wouters; Kathleen L J Daenen; Kim M Smits; Yoshimitsu Akiyama; Yasuhito Yuasa; Silvia Sanduleanu; Carolina A J Khalid-de Bakker; Daisy Jonkers; Matty P Weijenberg; Joost Louwagie; Wim van Criekinge; Beatriz Carvalho; Gerrit A Meijer; Stephen B Baylin; James G Herman; Adriaan P de Bruïne; Manon van Engeland
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

10.  A simplified, noninvasive stool DNA test for colorectal cancer detection.

Authors:  Steven Itzkowitz; Randall Brand; Lina Jandorf; Kris Durkee; John Millholland; Linda Rabeneck; Paul C Schroy; Stephen Sontag; David Johnson; Sanford Markowitz; Lawrence Paszat; Barry M Berger
Journal:  Am J Gastroenterol       Date:  2008-08-27       Impact factor: 10.864

View more
  12 in total

1.  Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer.

Authors:  Xuan-di Wu; Yong-Chun Song; Pei-Long Cao; Hao Zhang; Qi Guo; Rong Yan; Dong-Mei Diao; Yao Cheng; Cheng-Xue Dang
Journal:  Med Oncol       Date:  2014-02-27       Impact factor: 3.064

2.  Detection of hypermethylated fibrillin-1 in the stool samples of colorectal cancer patients.

Authors:  Qi Guo; Yongchun Song; Hao Zhang; Xuandi Wu; Peng Xia; Chengxue Dang
Journal:  Med Oncol       Date:  2013-08-21       Impact factor: 3.064

3.  Detection of SNCA and FBN1 methylation in the stool as a biomarker for colorectal cancer.

Authors:  Wen-han Li; Hao Zhang; Qi Guo; Xuan-di Wu; Zi-sen Xu; Cheng-xue Dang; Peng Xia; Yong-chun Song
Journal:  Dis Markers       Date:  2015-02-23       Impact factor: 3.434

4.  DNA methylation analysis of secreted frizzled-related protein 2 gene for the early detection of colorectal cancer in fecal DNA.

Authors:  Hadi Babaei; Mohsen Mohammadi; Rasoul Salehi
Journal:  Niger Med J       Date:  2016 Jul-Aug

5.  A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.

Authors:  María Gallardo-Gómez; Sebastian Moran; María Páez de la Cadena; Vicenta Soledad Martínez-Zorzano; Francisco Javier Rodríguez-Berrocal; Mar Rodríguez-Girondo; Manel Esteller; Joaquín Cubiella; Luis Bujanda; Antoni Castells; Francesc Balaguer; Rodrigo Jover; Loretta De Chiara
Journal:  Clin Epigenetics       Date:  2018-04-16       Impact factor: 6.551

Review 6.  DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer.

Authors:  Catherine Leygo; Marissa Williams; Hong Chuan Jin; Michael W Y Chan; Wai Kit Chu; Michael Grusch; Yuen Yee Cheng
Journal:  Dis Markers       Date:  2017-09-05       Impact factor: 3.434

7.  Evaluating gut microbiota profiles from archived fecal samples.

Authors:  Trine B Rounge; Roger Meisal; Jan Inge Nordby; Ole Herman Ambur; Thomas de Lange; Geir Hoff
Journal:  BMC Gastroenterol       Date:  2018-11-08       Impact factor: 3.067

8.  Detection of hypermethylated spastic paraplegia-20 in stool samples of patients with colorectal cancer.

Authors:  Hao Zhang; Yong-Chun Song; Cheng-Xue Dang
Journal:  Int J Med Sci       Date:  2013-01-13       Impact factor: 3.738

9.  Comparative DNA methylation among females with neurodevelopmental disorders and seizures identifies TAC1 as a MeCP2 target gene.

Authors:  Kimberly A Aldinger; Jasmine T Plummer; Pat Levitt
Journal:  J Neurodev Disord       Date:  2013-06-11       Impact factor: 4.025

Review 10.  Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.

Authors:  Sarah Derks; Arjen H G Cleven; Veerle Melotte; Kim M Smits; Johann C Brandes; Nilofer Azad; Wim van Criekinge; Adriaan P de Bruïne; James G Herman; Manon van Engeland
Journal:  Cancer Metastasis Rev       Date:  2014-03       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.